Merck & Co., Inc. is 56.0x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($294.13 B vs $5.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APLS | MRK |
|---|---|---|
| Market cap | $5.25 B | $294.13 B |
| US-listed rank | #1353 | #44 |
| Revenue (latest FY) | $1.00B | $65.01B |
| Net income (latest FY) | $22.39M | $18.25B |
| Net margin | 2.2% | 28.1% |
| P/E (trailing FY) | 234.6 | 16.1 |
| SEC filings | 1,217 | 996 |
Merck & Co., Inc. is 56.0x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($294.13 B vs $5.25 B).
In their latest fiscal years, Apellis Pharmaceuticals, Inc. reported $1.00B in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Apellis Pharmaceuticals, Inc. and Merck & Co., Inc., or browse the full rankings.